Skip to main content

Market Overview

Oppenheimer: Axovant Deal Transform Pipeline

Oppenheimer: Axovant Deal Transform Pipeline

Axovant Sciences Ltd (NASDAQ: AXON) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease.

As some experts see it, the drug could be a game changer.

The Rating

Oppenheimer analysts Jay Olson and Silvan Tuerkcan maintained a Perform rating on the stock.

The Thesis

By the analysts’ assessment, the AXO-Lenti-PD candidate improves on the efficacy and dosing constraints of its ProSavin precursor, which heightens its prospects.

“We believe [the] deal leverages AXON's expertise in early and late-stage clinical development along with pre-launch commercial capabilities,” Olson and Tuerkcan wrote in a note.

It additionally pivots Axovant’s pipeline from small molecules to gene therapy — a play advancing a larger strategy expected to unfold throughout the year.

“We are encouraged by the rapid progress of new CEO Pavan Cheruvu as he quickly implements his vision for a new AXON that is focused on transformational science,” they wrote.

The old Axovant had been built on an Alzheimer's drug that eventually failed clinical trials last September. The stock faded 94 percent off that candidate's discontinuation but picked up on the latest opportunity.

Price Action

At time of publication, shares were trading up 40.2 percent at a rate of $6.38. The stock was trading under the $2 level before Wednesday's news.

Related Links:

Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant

The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Latest Ratings for AXON

Feb 2021JP MorganDowngradesOverweightNeutral
Feb 2021Morgan StanleyInitiates Coverage OnOverweight
Dec 2018JefferiesUpgradesHoldBuy

View More Analyst Ratings for AXON
View the Latest Analyst Ratings


Related Articles (AXON)

View Comments and Join the Discussion!

Posted-In: Jay Olson Oppenheimer Parkinson’s Disease Silvan TuerkcanAnalyst Color Reiteration Top Stories Analyst Ratings Best of Benzinga

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at